Penumbra, Inc. is a medical device company that designs, develops, manufactures, and markets products for the treatment of vascular diseases, with a primary focus on thrombectomy and embolization. The company’s portfolio includes technologies for removing blood clots associated with ischemic stroke, pulmonary embolism, deep vein thrombosis, and acute limb ischemia, as well as products for aneurysm treatment and vascular access. Penumbra operates in a single segment and serves specialist physicians and healthcare providers globally, selling directly in the United States, Europe, Canada, Australia, and Singapore, and through distributors in other international markets. Founded in 2004, the company introduced its first products to the thrombectomy market in 2007 and has since expanded into the access, embolization, and neurosurgical markets. In January 2026, Penumbra entered into an agreement to be acquired by Boston Scientific Corporation. The company previously operated an immersive healthcare business, which it ceased selling and wound down during 2024.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage penumbrainc.com
Sector Healthcare IR page penumbrainc.com/investors
Tags
thrombectomy, ischemic stroke, pulmonary embolism, deep vein thrombosis, acute limb ischemia, embolization, vascular access, endovascular, computer assisted vacuum thrombectomy, neurosurgical, CAVT, THUNDERBOLT
Press page penumbrainc.com/investors/press-releases

Metrics

Valuation  
Market cap $ 12.547B
Market cap (USD) $ 12.547B
P/E 80.19
PEG —
P/BV 7.92
P/S 8.04
P/OCF 48.06
P/FCF 62.64
Dividend yield —
Turnover / mcap —
Returns  
ROE 13.8%
ROI 14.1%
ROIC 13.0%
Profit margin 12.7%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 48
Quality score 38.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Revenue 1.404B 1.195B 1.059B 847.133M 747.59M 560.412M 547.405M 444.938M 333.764M 263.317M 186.095M 125.51M
Net profit 177.687M 14.012M 90.954M -2.002M 5.284M -15.702M 48.458M 6.601M 4.657M 14.814M 2.365M 2.245M
Free cash flow 174.934M 147.299M 82.12M -74.959M -11.678M -57.998M 4.543M 19.205M 159K -26.442M -27.753M -10.277M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Share price 310.91 237.48 251.54 222.46 287.32 175 164.27 122.2 94.1 63.8 53.81 —
Price performance 12m 0.31 -0.06 0.13 -0.23 0.64 0.07 0.34 0.3 0.47 0.19 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 43.3M 58M 81.9M 106M 115M 134M 203M 202M 168M 190M
↳ YoY growth +47.2% +33.9% +41.2% +29.3% +8.2% +16.9% +51.8% -0.8% -16.9% +13.3%
↳ 5y CAGR +41.1% +31.2% +25.3% +28.5% +19.8% +9.6% +10.6%
Lease liabilities (USD) — — 0.00 82.3M 77.3M 174M 236M 234M 223M 220M
Cash and deposits (USD) 13.2M 50.6M 67.9M 72.8M 69.7M 59.4M 69.9M 167M 324M 187M
Intangible assets (USD) 0.00 23.8M 27.2M 25.4M 10.6M 90.6M 81.2M 71.1M 6.51M 6.19M
Right-of-use assets (USD) — — 0.00 43.7M 41.2M 132M 193M 189M 178M 174M
Cash flow detail
Operating cash flow (USD) -12.8M 12.7M 28.8M 26.7M -33.2M 9.5M -55.7M 97.3M 168M 239M
Purchases of property, plant and equipment (USD) -13.6M -12.5M -9.6M -22.1M -24.8M -21.2M -19.3M -15.2M -21.2M -63.7M
Purchases of intangible assets (USD) 0.00 -2.5M 0.00 0.00 — — — — — —
Change in receivables (cash effect) (USD) -14.6M -9.12M -25.8M -25M -8.3M -21.3M -69.9M -266,000 26.6M -19.5M
Change in inventories (cash effect) (USD) -19.7M -18.8M -22.3M -41.4M -57M -51.6M -74.6M -67.7M -65.7M -26.5M
Change in payables (cash effect) (USD) 1.38M 1.85M 1.33M 6.04M -308,000 -1.57M 13.4M 1.1M 4.17M 3.07M
Share buybacks (cash effect) (USD) — — — — — — 0.00 0.00 -100M 0.00
Interest paid (cash effect) (USD) 0.00 — — — — — — — — —
Income taxes paid (cash effect) (USD) -2.15M -141,000 -156,000 -175,000 -1.41M -1.5M -2.92M -6.56M -20.7M -15.4M
Share-based compensation (USD) 14.6M 17.8M 18.4M 21.5M 25.5M 65.8M 37.4M 50.5M 46.2M 59.2M
Operating cash flow before change in receivables (USD) 1.75M 21.8M 54.6M 51.7M -24.9M 30.8M 14.2M 97.6M 142M 258M
Free cash flow (OCF - PPE - intangibles) (USD) -26.4M -2.34M 19.2M 4.54M -58M -11.7M -75M 82.1M 147M 175M
Income detail
Research and development expense (USD) 23.9M 31.7M 36.2M 51.7M 90M 105M 79.4M 84.4M 94.8M 89.8M
↳ 5y CAGR +20.8% +27.1% +37.9% +34.4% +20.2% +18.5% +12.9% -0.1%
Total comprehensive income (USD) 12.2M 10.9M -601,000 46.6M -14.4M -2.55M -7.5M 95.9M 11.3M 188M
Comprehensive income to owners (USD) 12.2M 10.9M 3.09M 48.1M -10.8M 113,000 -7.5M 95.9M 11.3M 188M
Provision for credit losses (USD) 216,000 606,000 1.56M 656,000 1.61M 0.00 -1.23M 2.31M 2.47M 368,000
Credit cost ratio (credit losses / average receivables) (%) 0.6% 1.2% 2.2% 0.7% 1.5% 0.0% 0.7% 1.1% 1.3% 0.2%
Reported Feb 27, 2018 Feb 27, 2018 May 7, 2019 Feb 26, 2020 Feb 23, 2021 Feb 22, 2022 Feb 18, 2025 Feb 18, 2025 Feb 18, 2025 Feb 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

ALAMEDA, Calif., Oct. 29, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2026.

•Revenue of $410.1 million in the third quarter of 2026, an increase of 15.6% compared to the third quarter of 2025.

•Global thrombectomy revenue of $279.2 million in the third quarter of 2026, an increase of 18.1% compared to the third quarter of 2025. U.S. VTE revenue increased 26.0% compared to the same period a year ago.

•Global embolization and access revenue of $131.0 million in the third quarter of 2026, an increase of 10.8% compared to the third quarter of 2025.

•U.S. neuro revenue of $77.9 million in the third quarter of 2026, an increase of 19.3% compared to the third quarter of 2025.

•Gross profit margin of 68.3% in the third quarter of 2026, an increase of 0.5% compared to the third quarter of 2025.

•Total operating expenses of $229.6 million in the third quarter of 2026, comprised of R&D of $25.4 million and SG&A of $204.2 million, which includes $7.1 million of acquisition-related expenses associated with the pending acquisition of Penumbra, Inc.

BOLT-DVT, a recent prospective, multicenter Investigational Device Exemption (IDE) trial, demonstrated first-line use of computer assisted vacuum thrombectomy (CAVT) for DVT is safe and effective

ALAMEDA, Calif., Oct. 20, 2026 /PRNewswire/ — Penumbra, Inc

. (NYSE: PEN), the world’s leading thrombectomy company, announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the treatment of deep vein thrombosis (DVT) to the company’s Lightning™ computer assisted vacuum thrombectomy (CAVT™) technology. This indication is supported by positive results from the BOLT-DVT Investigational Device Exemption (IDE) trial, which demonstrated the safety and efficacy of CAVT in treating DVT.

Bolt DVT Trial logo

“The standard treatment for DVT has been anticoagulation and there has not been a meaningful change in standard of care for decades,” said Patrick Muck, M.D., RVT, FACS, co-principal investigator of BOLT-DVT and vascular surgeon at TriHealth in Cincinnati, Ohio. “Anticoagulation primarily prevents clot progression and does little to remove the existing clot. The BOLT-DVT trial showed that CAVT delivered rapid clot removal, durable patient-reported pain relief and a low rate of re-thrombosis. The data resulted in the first cleared indication for the treatment of DVT amongst mechanical thrombectomy devices, underscoring the potential of CAVT to advance the treatment algorithm of DVT and improve patient outcomes.”

In the U.S., an estimated 900,000 cases of venous thromboembolism, which includes DVT and pulmonary embolism (PE), occur annually.[i] DVT can be a serious health condition because blood clots in the veins can break loose and travel through the bloodstream, potentially causing a PE, which can be a life-threatening medical emergency. BOLT-DVT enrolled patients with iliofemoral DVT, building on the historical precedent set by the ATTRACT randomized controlled trial but with modern technology. In BOLT-DVT, 98% of patients experienced complete or near-complete thrombus removal with a median device time of just 18 minutes and a low 48-hour major adverse event rate of 3.1%. These strong procedural outcomes were accompanied by a low re-thrombosis rate and improvements in patient-reported and clinician-assessed outcomes, including reduced pain and symptoms, and improved quality of life.

In the BOLT-DVT trial, treatment with CAVT successfully restored lower extremity deep venous flow in a single session,” said Kush R. Desai, M.D., FSIR, co-principal investigator of BOLT-DVT and interventional radiologist at Northwestern Medicine. “Perhaps more significant, patients felt immediate pain relief and by 30 days, there was significant improvement in venous stasis symptoms that included lower extremity pain and swelling. These findings provide clinicians with important evidence supporting the benefits of advanced intervention, such as CAVT, as a first-line treatment for acute iliofemoral DVT.”

Additional findings from the trial included:

  • No device-related deaths or serious device-related adverse events were observed

  • Low re-thrombosis rate of 3.9% within 30 days

  • High 30-day patency rates of 88.8%-96.3% across treated vessels

  • 84.3% of patients with no PTS symptoms (Villalta 0-4, no PTS) at 30 days

  • Median leg pain severity decreased from 5 (moderate to severe) at baseline to 0 (no pain) immediately post-procedure and 0 (no pain) at 30 days

  • Significant improvements in patient-reported overall quality of life at 30 days, with median VEINES-QOL scores improving from 49.3 to 84.2

“DVT remains an underestimated health issue that can lead to serious, potentially life-threatening complications,” said James F. Benenati, M.D., FSIR, chief medical officer at Penumbra. “This cleared treatment indication and the BOLT-DVT findings support advanced intervention for DVT and highlight the potential impact of CAVT on patient symptoms, quality of life and long-term clinical outcomes.”

Penumbra’s CAVT portfolio incorporates Lightning Flash™ technology, which utilizes pressure- and flow-based aspiration control algorithms during thrombectomy procedures to detect blood clot and blood flow. The portfolio is designed to facilitate clot removal with speed, safety and simplicity, allowing physicians to better navigate the body’s complex anatomy and deliver high power aspiration for clot removal.

Wearable-derived data provide new insights into how clinical outcomes for patients treated with CAVT and anticoagulation, and anticoagulation alone translate to patients’ everyday recovery

ALAMEDA, Calif., Oct. 6, 2026 /PRNewswire/ — Penumbra, Inc

. (NYSE: PEN) announced results from a subset analysis of the landmark STORM-PE

randomized controlled trial (RCT), the first trial to demonstrate a significant correlation between real-world, daily step-based activity as captured on a consumer wearable device and patient performance in the clinical 6-minute walk test. The findings were presented at this week’s Vascular InterVentional Advances (VIVA) meeting.

STORM-PE trial logo

STORM-PE RCT assessed patients with acute intermediate-high risk pulmonary embolism (PE) who were treated with computer assisted vacuum thrombectomy (CAVT™) plus anticoagulation compared to anticoagulation alone. Data from the trial showed patients treated with CAVT plus anticoagulation experienced improved right ventricular recovery and achieved greater functional improvement, including walking significantly further and a higher proportion of patients achieving NYHA Class I (no physical limitations)i compared to anticoagulation alone.

A cohort of the trial patients were discharged with a fitness watch to track a patient’s activity, including actigraphy measures during everyday living. STORM-PE investigators performed a correlation analysis between watch actigraphy (daily total step count, walking bout data, and daily peak steps) and made comparisons to the 6-minute walk test performed at 30- and 90-day follow-up visits.

“STORM-PE is the first RCT in pulmonary embolism therapy to incorporate data from a consumer wearable device, representing an important step forward in understanding how office assessed clinical improvements translate into meaningful real-world recovery,” said Robert Lookstein, M.D., MSc, global co principal investigator of the STORM PE RCT and professor of radiology and surgery at the Icahn School of Medicine at Mount Sinai. “This innovation enables the scientific community to determine whether improvements observed during office assessments are reflected in patients’ real-world experiences at home.”

Key findings of this subset analysis include:

  • Total daily step count, walking bout length, number of walking bouts, walking bout duration and peak 10-minute step count were significantly correlated with 30-day 6-minute walk test performance.

  • Correlations were strongest with temporally matched wearable and clinic data at 30 days and attenuated with 90-day follow up data.

  • Wearable technology provides a complementary measure of functional recovery after PE.

“This STORM-PE subset gives us a more complete picture of patient recovery by allowing us to compare data collected in the clinic with information gathered as patients go about their daily lives,” said Rachel Rosovsky, M.D., MPH, global co-principal investigator of the STORM PE RCT, hematologist at Massachusetts General Hospital, and associate professor of medicine at Harvard Medical School. “By generating a more comprehensive view of patient outcomes, these findings have the potential not only to advance our understanding of the role of endovascular therapy in PE, but also to help shape the design of future clinical trials.”

Complementing the STORM-PE findings, investigators presented a new interim analysis of 1,000 prospective patients from the STRIKE-PE trial, looking at one-year functional outcomes and quality of life for PE patients after CAVT during the 16th Venous Endovascular INterventional Strategies (VEINS) meeting. STRIKE-PE continues to support the safety and effectiveness of CAVT, including short device times and low adverse events, for treating PE. The study also found longer-term functional outcomes and quality of life benefits, including sustained reduced dyspnea, increased walking distance, restored functional status and improved quality of life. STRIKE-PE

is a prospective, international, multicenter study evaluating real-world safety, performance and long-term functional and quality-of-life outcomes of CAVT in up to 1,500 patients.

“At Penumbra, we are committed to advancing innovations that are supported by rigorous clinical evidence,” said James F. Benenati, M.D., FSIR, chief medical officer at Penumbra. “By incorporating consumer wearables into STORM-PE, we have a unique opportunity to evaluate whether the clinical improvements observed in traditional assessments are reflected in patients’ day-to-day recovery at home. Together with emerging data from STRIKE-PE, these findings contribute to a growing body of evidence supporting a significant role for CAVT in the treatment of PE.”

In the U.S., an estimated 900,000 cases of venous thromboembolism, including PE, occur annually.ii PE remains the third leading cause of cardiovascular death after heart attack and stroke.iii. Penumbra’s Lightning Flash™ portfolio is the most advanced mechanical thrombectomy system on the market, and the only CAVT system designed to address venous and pulmonary thrombus. It features Penumbra’s Lightning CAVT technology with the latest dual clot detection algorithms, using both pressure and flow-based processes to detect blood clot and blood flow. The portfolio is designed to help remove blood clots with speed, safety and simplicity, allowing physicians to better navigate the body’s complex anatomy and deliver high power aspiration for clot removal.

**About STORM-PE

**STORM-PE

is a pivotal, prospective, multi-center randomized controlled trial that enrolled 100 patients across 22 international sites to evaluate computer assisted vacuum thrombectomy (CAVT) using Penumbra’s Lightning Flash™ plus anticoagulation, versus anticoagulation alone, for the treatment of acute intermediate-high risk pulmonary embolism (PE). Conducted in partnership with The PERT Consortium®, the trial’s primary efficacy endpoint – reduction in RV/LV ratio at 48 hours – was assessed by a blinded independent core laboratory. All safety events were independently adjudicated by an external clinical events committee.

About Penumbra

Penumbra, Inc., the world’s leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT™), centers on removing blood clots from head-to-toe with speed, safety, and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com

and connect on Instagram

, LinkedIn

and X

.

Important Safety Information

Additional information about Penumbra’s products can be located on Penumbra’s website at https://www.penumbrainc.com/providers

. Caution: Federal (USA) law restricts these devices to sale by or on the order of a physician. Prior to use, please refer to the Instructions for Use (IFU) for complete product indications, contraindications, warnings, precautions, potential adverse events, and detailed instructions for use. Please visit www.peninc.info/risk

for the complete IFU Risk Summary Statements. The clinical results presented herein are for informational purposes only and may not be predictive for all patients. Individual results may vary depending on patient-specific attributes and other factors.

Forward-Looking Statements

Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: the risk that the pending acquisition by Boston Scientific Corporation will not be completed in the expected timeframe or at all, including the risk that required regulatory approvals will not be obtained; potential adverse effects to our business during the pendency of the acquisition, such as employee departures or diversion of management’s attention from our business; failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2025, which we filed on February 25, 2026. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.

| | |

| --- | --- |

| Contact | |

| | |

| Jennifer Heth | M+ |

| Penumbra, Inc | [email protected] |

| [email protected] | 310.600.6746 |

| 510-995-9791 | |

i STORM-PE was not powered to detect differences in safety

ii “Learn about Pulmonary Embolism,” American Lung Association. Accessed on Oct. 7, 2025. https://www.lung.org/lung-health-diseases/lung-disease-lookup/pulmonary-embolism/learn-about-pulmonary-embolism

iii “Pulmonary Embolism: A Clinical Approach,” American College of Cardiology. Accessed on Oct. 9, 2025. https://www.acc.org/Latest-in-Cardiology/Articles/2025/02/01/42/Cover-Story-Pulmonary-Embolism#:~:text=Pulmonary%20embolism%20(PE)%20continues%20to,venous%20thromboembolism%20in%20the%20country

Prompts

Penumbra, Inc. (ticker PEN), listed in United States.

ETFs Holding Penumbra, Inc.

ETF Weight in ETF Shares Market value As of
EVNT 2.54% 1,028 $ 332.147K Aug 31, 2026
CGMM 0.52% 58,570 $ 18.779M Nov 16, 2026
BTAL 0.40% 3,542 $ 1.118M Jun 30, 2026
FEMG 0.29% 62 $ 19.577K Jun 30, 2026
SYZ 0.29% 634 $ 200.186K Jun 30, 2026
SMDX 0.29% 1,154 $ 369.995K Nov 17, 2026
JMEE 0.27% 23,753 $ 7.58M Nov 17, 2026
DFAS 0.12% 120,809 $ 38.752M Nov 12, 2026
MSSM 0.07% 1,600 $ 516.96K Aug 31, 2026
RILA 0.07% 88 $ 28.265K Jul 31, 2026
DFAC 0.02% 53,163 $ 17.053M Nov 12, 2026
DCOR 0.02% 22,063 $ 7.077M Nov 12, 2026
DFAU 0.01% 6,022 $ 1.932M Nov 12, 2026
DFUS 0.01% 9,928 $ 3.185M Nov 12, 2026
MSLC 0.01% 1,433 $ 463.002K Aug 31, 2026
DFSU 0.01% 810 $ 259.824K Nov 12, 2026
AVUS 0.01% 2,607 $ 835.856K Nov 16, 2026
AVSU 0.01% 116 $ 37.192K Nov 16, 2026
AVLC 0.01% 617 $ 197.823K Nov 16, 2026
TMFS 0.01% 10 $ 3,231.00 Aug 31, 2026
FMDE 0.00% 603 $ 190.397K Jun 30, 2026
DYNF 0.00% 42 $ 13.466K Nov 16, 2026